Clinical trials: ACE Inhibitor-Induced Angioedema
ACE Inhibitor Induced Angioedema
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.
- Trial name
- NCT01343823
- Testing
- ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg
- Where
- 39 sites in United States
- Volunteers
- 79 people
- Sponsor
- Shire
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
This study is being conducted to compare the safety and efficacy of icatibant with placebo in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults.
- Trial name
- NCT01919801
- Testing
- Icatibant
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 118 people
- Sponsor
- Shire
Angioedema Caused by Angiotensin-Converting-Enzyme Inhibitor
Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema
Angiotensin Converting Enzyme (ACE) inhibitors are among the most important and widely prescribed drugs. They reduce the morbidity and mortality associated with high blood pressure, heart disease, and kidney disease.
- Trial name
- NCT04679311
- Testing
- High ACE Activity Fresh Frozen Plasma, Normal Saline
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine